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Abstract
A long form (tRNase Z
L) of tRNA 39 processing endoribonuclease (tRNase Z, or 39 tRNase) can cleave any target RNA at any
desired site under the direction of artificial small guide RNA (sgRNA) that mimics a 59-half portion of tRNA. Based on this
enzymatic property, a gene silencing technology has been developed, in which a specific mRNA level can be downregulated
by introducing into cells a synthetic 59-half-tRNA that is designed to form a pre-tRNA-like complex with a part of the mRNA.
Recently 59-half-tRNA fragments have been reported to exist stably in various types of cells, although little is know about
their physiological roles. We were curious to know if endogenous 59-half-tRNA works as sgRNA for tRNase Z
L in the cells.
Here we show that human cytosolic tRNase Z
L modulates gene expression through 59-half-tRNA. We found that 59-half-
tRNA
Glu, which co-immunoprecipitates with tRNase Z
L, exists predominantly in the cytoplasm, functions as sgRNA in vitro,
and downregulates the level of a luciferase mRNA containing its target sequence in human kidney 293 cells. We also
demonstrated that the PPM1F mRNA is one of the genuine targets of tRNase Z
L guided by 59-half-tRNA
Glu. Furthermore, the
DNA microarray data suggested that tRNase Z
L is likely to be involved in the p53 signaling pathway and apoptosis.
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Introduction
In 1989, we discovered a unique four-base-recognizing RNA
cutter termed RNase 65 in mammalian cytosolic extracts, which is
a ribonucleoprotein complex between a long form (tRNase Z
L)o f
tRNA 39 processing endoribonuclease (tRNase Z, or 39 tRNase)
and 39-truncated tRNA [1–3]. We have shown that RNase 65
recognizes substrate RNA via four base-pairings with the 59-
terminal sequence of the 39-truncated tRNA (Figure 1A), but its
role and genuine substrate RNA in the cells remain to be unveiled.
tRNase Z is one of the tRNA-maturing enzymes, which removes a
39 trailer from pre-tRNA [4,5]. In most cases, tRNase Zs cleave
pre-tRNAs immediately downstream of a discriminator nucleo-
tide, onto which the CCA residues are added to produce mature
tRNA (Figure 1A). In some cases, additional cleavages occur 1 nt
upstream, or 1 or 2 nt downstream. Although mammalian
genomes encode an ,100-kDa long form and an ,40-kDa short
form (tRNase Z
S), curiously, only tRNase Z
L can function as
RNase 65 [6].
The finding of RNase 65 encouraged us to pursue further
versatility of mammalian tRNase Z
L, and we have demonstrated in
vitro that tRNase Z
L can cleave any target RNA at any desired site
by recognizing a pre-tRNA-like or micro-pre-tRNA-like complex
formed between the target RNA and small guide RNA (sgRNA)
[7–12]. sgRNA is divided into four categories, 59-half-tRNA,
heptamer RNA, hook RNA, and ,12–16-nt linear RNA
(Figure 1A). Again, tRNase Z
S can process pre-tRNAs but not
the pre-tRNA-like or micro-pre-tRNA-like complexes in vitro [6].
We have also shown the efficacy of this RNA targeting method in
the living mammalian cells by introducing sgRNAs either as their
expression plasmids or as 29-O-methyl RNAs [13–16]. We call this
method TRUE gene silencing after tRNase Z
L-utilizing efficacious
gene silencing.
A huge number of novel small noncoding RNAs (ncRNAs) are
being revealed, which have roles in a great variety of cellular
processes [17,18]. MicroRNAs (miRNAs) are 21–23-nt RNAs that
can play important regulatory roles in many processes such as
development, cancer, and apoptosis [17]. We have shown that a
subset of miRNAs can guide target RNA cleavage by tRNase Z
L in
vitro, and that human miR-103 can downregulate the luciferase
gene expression through directing its mRNA cleavage by tRNase
Z
L [[8, unpublished data]].
Collectively, the cytosolic existence of RNase 65, the efficacy of
TRUE gene silencing, and the potential of miRNAs as sgRNAs
implied that a new broader gene regulatory system composed of
tRNase Z
L and small ncRNAs exists in the cells. In order to
illuminate this system, we started by trying to catch small RNAs
that are interacting with tRNase Z
L in the cells. In this study we
discovered in human kidney 293 cell extracts various new small
ncRNAs including piRNA-like 59-half-tRNAs and 28S rRNA
fragments, co-immunoprecipitated with tRNase Z
L, and demon-
strated that these ncRNAs work as sgRNAs for tRNase Z
L in vivo
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L exists
ubiquitously in a human cell. Taken together, the present data
suggest that human cytosolic tRNase Z
L modulates gene
expression through various types of small ncRNA. We also show
that PPM1F and DYNC1H1 mRNAs are its genuine targets, and
discuss its physiological roles.
Results
piRNA-like ncRNAs co-immunoprecipitate with human
tRNase Z
L
Since we were curious to know if other types of cellular small
ncRNAs could work as sgRNAs for tRNase Z
L, we tried to catch
Figure 1. Human tRNase Z
L and its substrates. (A) Various RNA substrates for human tRNase Z
L. Arrows denote the primary cleavage sites. (B) Two
forms of human tRNase Z
L. Double-headed arrows denote minimum regions for the activities [5,6]. y-His, pseudo histidine motif; His, histidine motif.
doi:10.1371/journal.pone.0005908.g001
59-Half-tRNA-Guided tRNase Z
L
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L in the cells by
isolating RNAs from 293 cell extracts which co-immunoprecipitate
with tRNase Z
L. We cloned and sequenced 26 RNAs of ,20–
40 nt, and identified 11 59-half or 39-half tRNA fragments, 6
rRNA fragments, 4 snRNA fragments, one fragment of the
DOCK9 pre-mRNA, and 4 RNA fragments of unknown origin
(Table S1). To our surprise, 6 tRNA fragments and all of the
rRNA fragments were very closely related to piRNAs, which have
been found in germ line cells [18]. One of the snRNA fragments,
the U6B snRNA fragment, also matched with an mRNA for a b-
actin-like protein. Some of these RNAs may be background noise
since we also identified one 18S rRNA fragment in a negative
control. To confirm that these tRNase Z
L-interacting small
ncRNAs really exist in the cells, we performed northern analysis
for the several representative ncRNAs. Although the expression
levels differed with the species, most of the ncRNAs were detected
in both 293 and HeLa cells, and the 59-half-tRNA
Glu was
predominant in the cytoplasm in the 293 cells (Figure S1).
Recently, other groups have also reported that 59-half and 39-half
tRNA fragments exist stably in various types of cells, although little
is know about their physiological roles [19–23].
59-half-tRNA
Glu functions as sgRNA in vitro
The two 59-half-tRNAs among the tRNase Z
L-co-immunopre-
cipitated ncRNAs especially attracted us to further investigation
since these 59-half-tRNAs are the very RNAs that we have been
using as tailor-made sgRNAs for specific gene silencing by tRNase
Z
L. We examined a 59-half-tRNA
Glu for its capability for sgRNA
in vitro. A target RNA, target-2, was designed to include a sequence
partially complementary to each RNA and to form a pre-tRNA-
like structure, when bound (Figure 2C). As we show below, there
exist two forms of human tRNase Z
L, full-length and N-terminal-
truncated ones (Figures 1B and 2A). We first tested D30 tRNase Z
L
lacking the N-terminal 30 amino acids, which are predicted to
correspond to the mitochondrial transport signal [24]. The target-
2 was efficiently cleaved at the expected 39th-nt site in the
presence of the 59-half-tRNA
Glu but not in the presence of the 30-
nt 28S rRNA fragment that was co-immunoprecipitated with
tRNase Z
L (Figure 2D). We also tested full-length tRNase Z
L for
cleavage of the complex. The full-length enzyme was slightly less
active than the D30 one (Figure 2E), whereas both enzymes
cleaved pre-tRNA
Arg with the same efficiency (Figure 2B).
We also found that the 28S rRNA fragment can form a hook
structure and thus can potentially work as sgRNA (Figures 1A and
2F) [9]. To examine if this is the case, we designed the RNA
target-3 to form a micro-pre-tRNA-like structure with the 28S
rRNA fragment (Figure 2F). The target-3 was cleaved at the
expected 12th-nt site only in the presence of the 28S rRNA
fragment (Figure 2G), and in this case, the D30 tRNase Z
L was
much more active than the full-length enzyme (Figure 2H),
indicating that the 28S rRNA fragment indeed works as hook-type
sgRNA.
Human tRNase Z
L exists ubiquitously in cells
If tRNase Z
L really works with 59-half-tRNA
Glu, which is
predominant in the cytoplasm, it would need to exist in the cytosol
as well as in the nuclei and the mitochondria, where the tRNA 39
processing occurs. And the above in vitro observation implies that
the cytosolic form should be the D30 tRNase Z
L rather than the
full-length one. We examined the intracellular location of tRNase
Z
L by the indirect fluorescent method using polyclonal antibodies
against a human tRNase Z
L peptide (C-terminal amino acid 812–
826). Fluorescent microscopic analysis showed that tRNase Z
L
exists everywhere in the 293 cells although the amount of the
nuclear tRNase Z
L appears to vary depending on the cells
(Figures 3 and S2). The similar distribution patterns were observed
in human A549 epithelial lung adenocarcinoma cells, HepG2
hepatoma cells, and IMR90 lung fibroblasts (Figure 3 and S2),
suggesting that tRNase Z
L is ubiquitous in any type of human cells.
D30 tRNase Z
L exists primarily in the cytosol
Western blotting showed that in the 293 cells exist ,98- and
,94-kDa forms of tRNase Z
L, which correspond to the full-length
and D30 enzymes, respectively (Figure 4A). To elucidate a
subcellular distribution of these two forms, we carried out the
western analysis for tRNase Z
L in subcellular fractions, and found
that, as expected, the D30 form exists primarily in the cytosolic
fraction while the full-length form is primarily in the nuclear
fraction (Figure 4B). Both forms were also found in the
membrane/organelle fraction.
Introduction of the tRNase Z
L expression plasmid or the
tRNase Z
L siRNA into the 293 cells changed the level of the D30
form more drastically than that of the full-length one (Figure 4C).
This observation suggests that there may be a mechanism to
maintain the full-length tRNase Z
L level in the nuclei and that the
role of the nuclear tRNase Z
L may be more important than that of
the cytosolic D30 tRNase Z
L.
59-half-tRNA
Glu works as sgRNA in vivo
Next, we performed in vivo analysis using a luciferase reporter
plasmid modified to contain the target sequence in the 39 UTR.
The expression level from the luciferase mRNA mlucT(tRNA)
containing the 59-half-tRNA
Glu target sequence was decreased by
adding the synthetic 59-half-tRNA
Glu into the 293 cells compared
with that from the normal luciferase mRNA mlucT0 (Figure 5A).
The downregulation level was augmented by over-expressing
tRNase Z
L and lowered by decreasing the tRNase Z
L level
(Figure 5A,B). In contrast, the over-expression of tRNase Z
S
slightly decreased the downregulation level, and the Ago2
downregulation did not affect the expression significantly. The
same effect of the change in the tRNase Z
L level on the
mlucT(tRNA) amount itself was also observed (Figure 5C). We
also analyzed 39-end sequences of 59 cleavage products from
mlucT(tRNA), and identified the 39 ends at 6- to 30-nt upstream of
the expected tRNase Z
L cleavage site (Figure 5D). The shorter
cleavage products could be due to 39 to 59 exoribonuclease
reactions after the tRNase Z
L cleavage, although there is no direct
evidence yet. In contrast, we could not clone any fragments from
the unmodified luciferase mRNA, supporting the involvement of
the 59-half-tRNA
Glu as sgRNA in the cleavage of mlucT(tRNA). In
the similar fashion, the 28S rRNA fragment and tRNase Z
L
affected the expression from mlucT(rRNA) containing the target
sequence of the 28S rRNA fragment (Figure 5A).
The PPM1F mRNA is a genuine target of tRNase Z
L
guided by 59-half-tRNA
Glu
Taken together, these results imply that tRNase Z
L together
with naturally occurring small ncRNAs plays a role in regulation
of gene expression. In order to find genuine mRNA targets of
tRNase Z
L guided by ncRNAs, we performed DNA microarray
analysis for mRNAs from the 293 cells transfected with the tRNase
Z
L expression plasmid. The expressions of 41 and 310 genes were
downregulated and upregulated by .1.5-fold, respectively, in the
presence of a higher level of tRNase Z
L. It is likely that a subset of
the 41 downregulated mRNAs are direct targets of tRNase Z
L
(Figure S3A). The Kyoto Encyclopedia of Genes and Genomes
(KEGG) pathway analysis (http://www.genome.ad.jp/kegg) [25]
59-Half-tRNA-Guided tRNase Z
L
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Glu and a 28S rRNA fragment function as sgRNAs in vitro. (A) Purified histidine-tagged full-length and D30 tRNase
Z
L proteins separated on an SDS/polyacrylamide gel. (B) 59-fluorescein-labeled pre-tRNA
Arg was reacted with the full-length and D30 enzymes for
5 min, and the products were analyzed on a denaturing polyacrylamide gel. I, input. (C) A secondary structure of the 59-half-tRNA
Glu/target-2 RNA
complex. An arrow denotes the primary cleavage site. (D) 59-fluorescein-labeled target-2 was incubated with recombinant human D30 tRNase Z
L in
the absence or presence of the 59-half-tRNA
Glu or the 28S rRNA fragment. The cleavage products were analyzed on a denaturing polyacrylamide gel.
L, alkaline ladder of the target-2; I, input. (E) The 59-half-tRNA
Glu/target-2 complex was also reacted with the full-length and D30 enzymes for 5 min.
(F) A secondary structure of the 28S rRNA fragment/target-3 RNA complex. An arrow denotes the primary cleavage site. (G) 59-fluorescein-labeled
target-3 was incubated with recombinant human D30 tRNase Z
L in the absence or presence of the 59-half-tRNA
Glu or the 28S rRNA fragment. The
cleavage products were analyzed on a denaturing polyacrylamide gel. 14, 14-nt size standard; L, alkaline ladder; I, input. (H) The cleavage reactions
were also performed with the full-length and D30 enzymes for 5 min.
doi:10.1371/journal.pone.0005908.g002
59-Half-tRNA-Guided tRNase Z
L
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L is involved in the p53 signaling pathway
and apoptosis with P values=1.3610
26 and=4.2610
24, respec-
tively (Figure S3B,C). We also searched a human mRNA database
(http://www.ncbi.nlm.nih.gov) for potential mRNA targets of
tRNase Z
L guided by 59-half-tRNA
Glu, and retrieved 432 mRNAs,
which contain one to nine potential binding sites for 59-half-
tRNA
Glu (Table S2). The criteria of its binding site are the
presence of 7-nt downstream and 3- to 5-nt upstream sequences
that are complementary to the acceptor-stem and anticodon-stem
domain sequences, respectively, of the 59-half-tRNA
Glu, and a T-
arm-like structure in between. DYNC1H1, LYPLA2, MXD4,
PBX2, PPM1F, RBM6, SREBF2, and ZNF609 mRNAs were
found in both groups (Figure S3A and Table S2).
To identify specific mRNA targets of tRNase Z
L directed by 59-
half-tRNA
Glu, we arbitrarily selected DYNC1H1, KIF1A, LY-
PLA2, PPM1F, RBM6, SREBF2, ZFAND6, ZNF609, and
ZDHHC20 mRNAs from the mRNAs downregulated in the
presence of a higher level of tRNase Z
L (Figure S3A), and
CTDSP2, FOXP2, and HDAC4 mRNAs from the potential 59-
half-tRNA
Glu target mRNAs (Table S2), and analyzed changes in
their amounts in response to the change in the intracellular level of
the 28S rRNA fragment, the 59-half-tRNA
Glu, or tRNase Z
L. First,
we performed non-quantitative reverse-transcription PCR analysis
to see the changes in mRNA levels using the 28S rRNA level as an
internal standard, and observed obvious changes in the PPM1F,
DYNC1H1, and HDAC4 mRNA levels (Figure S4). These
mRNAs contain 0, 6, and 9 potential 28S rRNA fragment
binding sites, and 3, 1, and 2 potential 59-half-tRNA
Glu binding
sites, respectively. Possible secondary structures of 59-half-tRNA-
Glu/PPM1F mRNA complexes are exampled in Figure S5. There
were no obvious changes in the levels of the other mRNAs such as
FOXP2 mRNA (Figure S4 and data not shown). The PPM1F
mRNA level was decreased by increasing the level of 59-half-
tRNA
Glu or tRNase Z
L, but not affected by increasing the 28S
rRNA fragment level, whereas the DYNC1H1 mRNA level was
decreased by increasing the level of the 28S rRNA fragment or
tRNase Z
L, but not affected by increasing the 59-half-tRNA
Glu
level. Curiously, the HDAC4 mRNA level increased with the
increase in the level of 59-half-tRNA
Glu or tRNase Z
L, but did not
change by increasing the 28S rRNA fragment level. On the whole,
multiple target sites in an mRNA for an ncRNA appear to be
essential for efficient downregulation, although obviously this rule
does not hold in the HDAC4 case.
To confirm and quantitate the changes in the mRNA levels, we
carried out real-time PCR using different pairs of primers. Again,
the PPM1F mRNA level was downregulated up to less than 50%
by increasing the level of 59-half-tRNA
Glu or tRNase Z
L, and the
DYNC1H1 mRNA level was downregulated up to ,50% by
increasing the level of the 28S rRNA fragment or tRNase Z
L
(Figure 6). The DYNC1H1 mRNA level decreased further up to
Figure 3. Human tRNase Z
L exists ubiquitously in cells. Fluorescent microscopic analyses of human 293 kidney cells, A549 epithelial lung cells,
HepG2 hepatoma cells, and IMR90 lung fibroblasts. The cells were incubated with primary tRNase Z
L antibodies and subsequently with an Alexa488-
conjugated secondary antibody (Alexa488). Negative control pictures are shown in Figure S2. DAPI was used to stain DNA (DAPI), and MitoTracker
Red was to stain the mitochondria (MitoTracker). Bar, 20 mm.
doi:10.1371/journal.pone.0005908.g003
59-Half-tRNA-Guided tRNase Z
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L exists primarily in the cytosol. (A) Western blotting for human tRNase Z
L from the 293 cells. The recombinant full-
length and D30 tRNase Z
L standards were generated from intein-fusion proteins. The membrane was probed with antibodies raised to a human
tRNase Z
L peptide (amino acid 812–826). (B) Western analyses for human tRNase Z
L in the subcellular fractions. The cytosolic (F1), membrane/
organelle (F2), nuclear (F3), and cytoskeletal (F4) fractions were prepared from the 293 cells. (C) Total protein samples from the 293 cells that were
transfected with the tRNase Z
L expression plasmid (+Z
L) or with the tRNase Z
L siRNA (2Z
L) were subjected to western analyses.
doi:10.1371/journal.pone.0005908.g004
Figure 5. 59-half-tRNA
Glu works as sgRNA in vivo. (A) Luciferase assays with the 293 cells. The ratio of the expression level from mlucT(tRNA) or
mlucT(rRNA) to that from the unmodified luciferase mRNA mlucT0 is shown in the 293 cells that were co-transfected with 59-half-tRNA
Glu (+tRNA), the
28S rRNA fragment (+rRNA), the tRNase Z
L expression plasmid (+Z
L), the tRNase Z
S expression plasmid (+Z
S), the tRNase Z
L siRNA (2Z
L), or the Ago2
siRNAs (2Ago). Two independent sets of data are presented, and error bars indicate s.d. (n=3). Asterisk, P,0.01. (B) Western blotting for tRNase Z
L,
Ago2, and tRNase Z
S in the 293 cells that were transfected with the above plasmids or siRNAs. (C) The ratio of the mlucT(tRNA) amount to the mlucT0
amount in the 293 cells quantitated by real-time PCR. Two independent sets of data are presented, and error bars indicate s.d. (n=3). Asterisk,
P,0.05. (D) Distribution of 39 ends of 59 cleavage products of mlucT(tRNA). Red line, expected cleavage site.
doi:10.1371/journal.pone.0005908.g005
59-Half-tRNA-Guided tRNase Z
L
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tRNase Z
L, while the decrease in the PPM1F mRNA level was
hardly affected by increasing both levels of 59-half-tRNA
Glu and
tRNase Z
L, suggesting that about half of the PPM1F mRNA
molecules may be protected from degradation by somehow
compartmentalizing them. The HDAC4 mRNA level upregulated
up to 2.9-, 1.7-, and 3.8-fold by increasing the levels of 59-half-
tRNA
Glu, tRNase Z
L, and both, respectively (Figure 6).
We also analyzed 39-end sequences of 59 cleavage products from
the PPM1F mRNA, and identified the 39 ends at 6- and 43-nt
upstream of the first site of the three expected tRNase Z
L cleavage
sites (Figures S5 and S6). The shorter cleavage products could
have been caused by 39 to 59 exoribonuclease reactions after the
tRNase Z
L cleavage. No PPM1F mRNA cleavage products were
detected at the other two sites.
These results suggest that the PPM1F and DYNC1H1 mRNAs
are genuine targets of tRNase Z
L guided by 59-half-tRNA
Glu and
the 28S rRNA fragment, respectively. In support of this, one out of
three potential 59-half-tRNA
Glu-guided tRNase Z
L target sequenc-
es in the human PPM1F mRNA and all six potential 28S-rRNA-
fragment-guided tRNase Z
L target sequences in the human
DYNC1H1 mRNA are well conserved among human, mouse,
and rat at most with single base-pair-disrupting nt substitutions in
the ncRNA-binding sites (Figure S7). The mouse and rat
sequences corresponding to the downstream 59-half-tRNA
Glu-
binding sequence in the second target site of the human PPM1F
mRNA contain triple base-pair-disrupting nt substitutions (Figure
S7A), and mouse and rat sequences corresponding to the third
target sequence in the 39 UTR of the human PPM1F mRNA are
not discernible. Together with the observation that the human
PPM1F mRNA fragments were detected only at the first target site
(Figure S6), these suggest that the second and third target sites
might not be used in human cells also. The unexpected changes in
the HDAC4 mRNA level would be explained by assuming that the
HDAC4 mRNA level is downregulated by proteins from some
mRNAs and/or some ncRNAs, the levels of which are
downregulated by tRNase Z
L guided by 59-half-tRNA
Glu.
Discussion
Origin of tRNase Z
L-interacting ncRNA
We identified 26 small RNA species of ,20–40 nt that co-
immunoprecipitated with human tRNase Z
L. These RNAs are 11
tRNA fragments, 6 rRNA fragments, 4 snRNA fragments, one
fragment of the DOCK9 pre-mRNA, and 4 RNA fragments of
unknown origin (Table S1). The existence of some of these RNAs
in the cells was shown by northern analysis (Figure S1). We believe
that the fragments of tRNAs, rRNAs, and snRNAs would function
as sgRNAs and that the 4 RNA fragments of unknown origin may
be parts of target mRNAs to be cleaved by cytosolic D30 tRNase
Z
L under the direction of cellular ncRNAs functioning as sgRNAs.
If the 21-nt RNA that matches with the U6B snRNA fragment
turns out to be from the mRNA for the b-actin-like protein, this
RNA may be also a target of cytosolic D30 tRNase Z
L. The
fragment of the DOCK9 pre-mRNA is from one of its introns,
suggesting that the DOCK9 expression may be modulated by
nuclear tRNase Z
L under the direction of nuclear small ncRNA
and/or that this RNA fragment, which is generated from the
intron through an as yet unknown mechanism, may work as
sgRNA. Although we showed that the 59-half-tRNA
Glu and the
28S rRNA fragment work as 59-half-tRNA-type and hook-type
sgRNAs, respectively, we do not necessarily know the guiding
modes of the other newly identified ncRNAs. It is also possible that
39-half-tRNAs function as 59-half-tRNA-type sgRNA.
Although we do not know currently how these potential
sgRNAs are generated from tRNAs, rRNAs, and snRNAs, we
would like to propose possible pathways for generation of half-
tRNA fragments, which are not mutually exclusive (Figure 7). A
free tRNA molecule may be cleaved in the anticodon loop by
some specific endoribonuclease(s) to produce 59-half-tRNA and 39-
half-tRNA molecules. This tRNA molecule to be processed may
be a functional one or a non-functional misfolded one.
Figure 6. PPM1F and DYNC1H1 mRNAs are targets of ncRNA-
guided tRNase Z
L. Total RNA was extracted from the 293 cells that
were transfected with 59-half-tRNA
Glu (+tRNA) or the 28S rRNA fragment
(+rRNA) and/or the tRNase Z
L expression plasmid (+Z
L), and analyzed by
real-time PCR. The mRNA levels are normalized against the 28S rRNA
levels. Error bars indicate s.d. (n=3). Asterisk, P,0.005.
doi:10.1371/journal.pone.0005908.g006
59-Half-tRNA-Guided tRNase Z
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processed likewise, because the acceptor stem and the T arm are
the minimum requirements for tRNase Z
L recognition and the
anticodon loop would be accessible to another enzyme. In this
case, the 39-half-tRNA molecule may be discarded and the 59-half-
tRNA molecule may be used directly as sgRNA inside tRNase Z
L.
The discarded 39-half-tRNA molecule may be also used as 59-half-
tRNA-type sgRNA by another tRNase Z
L molecule. Recently, the
RNase T2 family member Rny1 and the RNase A family member
angiogenin have been shown to be responsible for the half-tRNA
generation in yeast and human cells, respectively [22,23]. Another
possibility is that the half-tRNA molecules may be generated as
splicing intermediate molecules from intron-containing tRNAs. In
any case, tRNA sources would be from genuine gene transcripts
and/or from pseudogene transcripts, because the highly conserved
A58 was substituted with U58 in six cases and with C58 in one case
among the nine 39-half-tRNAs (Table S1).
The D30 form of human tRNase Z
L
We identified two forms of human tRNase Z
L: one is the
nuclear full-length form and the other is the cytosolic D30 form
(Figure 4B). Both forms are also found in the membrane/organelle
fraction. Since the N-terminal 30 amino acids are predicted to be a
mitochondrial transport signal [24], probably the full-length form
would be one that is bound to the mitochondrial membrane and is
waiting for processing, whereas the D30 form would be a
processed one inside the mitochondria. The nuclear transport of
the full-length tRNase Z
L would be accomplished through a
potential nuclear localization signal, 28RRERPRKD35, at the N-
terminal region [26]. We, however, do not know a mechanism for
generation of the D30 form in the cytosol. The mitochondrial D30
enzyme may be retrograde-transported to the cytosol, or some
specific processing enzyme in the cytosol may be responsible for its
production. In any case, once the D30 form is generated in the
cytosol, it would be hardly transported to the nucleus, because the
D30 enzyme lacks the first three amino acids of the potential
nuclear localization signal. This is consistent with the observation
that the D30 form was barely detected in the nuclear fraction
(Figure 4B).
Curiously, the D30 tRNase Z
L was much more active than the
full-length enzyme on the 28S rRNA fragment/target-3 complex,
whereas the activities of both enzymes were the same on the pre-
tRNA
Arg substrate (Figures 2B,H). With respect to the 59-half-
tRNA
Glu/target-2 complex, the D30 form was slightly more active
than the full-length one (Figure 2E). These observations imply that
the N-terminal 30 amino acids may somehow inhibit the
recognition of micro-pre-tRNA-like complexes by tRNase Z
L.
To elucidate the structural basis for this issue, we are currently
trying to solve crystal structures of both forms with RNA
substrates.
Proteins that interact with human tRNase Z
L
Because human tRNase Z
L exists everywhere in the cells
(Figure 3) and is a relatively large enzyme, it would be expected
tointeractphysicallywithotherproteins.Indeed,humantRNaseZ
L
has been shown to interact with c-tubulin and two other protein
components of the c-tubulin ring complex by co-immunoprecipi-
tation experiments [27]. The interactionbetween tRNase Z
L and a-
tubulin, however, has not been observed, suggesting that human
tRNase Z
L interacts with a free form of the c-tubulin ring complex.
By co-immunoprecipitation experiments with the tRNase Z
L
antibodies, we confirmed the tRNase Z
L/c-tubulin interaction
and found that tRNase Z
L also interacts with myosin II under some
conditions (data not shown). Consistent with this, D30 tRNase Z
L
was detected in the cytoskeletal fraction by the western analysis for
tRNase Z
L in subcellular fractions from the 293 cells transfected
with the tRNase Z
L expression plasmid (data not shown).
Human tRNase Z
L was also reported to interact with Smad2 to
function as a transcription factor by co-immunoprecipitation
experiments using exogenously expressed tagged human tRNase
Z
L [28]. Although this observation is potentially very intriguing,
we could not detect this interaction with respect to endogenous
human tRNase Z
L.
Genuine targets and physiological roles
We found that the DYNC1H1 mRNA is likely to be a genuine
target of tRNase Z
L (Figure 6), and the two RNA fragments co-
immunoprecipitated with tRNase Z
L suggest that the b-actin-like
protein mRNA and the DOCK9 pre-mRNA may also be genuine
targets (Table S1). The dynein’s function and putative functions of
the b-actin-like protein and DOCK9 [29,30] together with the
presence of the c-tubulin/tRNase Z
L and myosin II/tRNase Z
L
interactions [27] (data not shown) appear to converge at the
supposition that tRNase Z
L is involved in regulation of mitosis.
The DNA microarray data suggested that tRNase Z
L is likely to
be involved in the p53 signaling pathway and apoptosis (Figure
S3B,C), and PPM1F, the mRNA of which was identified as a
target of tRNase Z
L guided by 59-half-tRNA
Glu (Figure 6), has
been shown to induce apoptosis in HeLa cells when overexpressed
[31]. Interestingly, calcium/calmodulin-dependent protein kinase
II, which is regulated by PPM1F in fibroblasts [32], phosphory-
lates the product of the HDAC4 mRNA [33], the level of which
was upregulated by tRNase Z
L and 59-half-tRNA
Glu (Figure 6).
Furthermore, the observations that the 59-half-tRNA
Glu level in
both 293 and HeLa cells increases with the increase in cell density
(Figure S8A) and that the level of the RNase 65 RNA component
39-truncated tRNA
Arg increases in BJAB cells after adding 5-
fluorouracil (Figure S8B) suggest their relevance to cell cycle
regulation and apoptosis. To harmonize some events of mitosis,
ncRNA-guided tRNase Z
L, the activity of which may be
modulated by c-tubulin and/or myosin II, may play a pivotal
role through controlling the levels of mRNAs that produce key
proteins for mitosis.
Materials and Methods
tRNase Z
L preparation
The histidine-tagged human full-length and D30 tRNase Z
L
proteins were over-expressed from the expression plasmid pQE-
Figure 7. Mechanisms for generation of half-tRNAs as sgRNAs.
See text for a detailed description. Possible pathways for generation of
half-tRNA fragments that can be used as sgRNAs.
doi:10.1371/journal.pone.0005908.g007
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purified with nickel-agarose beads [6]. The human full-length and
D30 tRNase Z
L proteins were also over-expressed from the
expression plasmid pTYB11 (New England BioLabs) in the same
strain and purified with chitin beads [5]. To check their purity, the
proteins were separated on an SDS-7.5% polyacrylamide gel, and
visualized by staining the gel with Coomassie brilliant blue R-250.
RNA synthesis
Two target RNAs were synthesized with T7 RNA polymerase
(Promega) from the corresponding synthetic DNA templates. The
sequences of these RNAs are as follows: target-2, 59-GAGCUAU-
UGCGCCGCUGGGUUGGAUUCCCAGCCAGGGAAGGCU-
UCU-39; target-3, 59-GAGGACUUUCUUGGUUUACUAUUG-
39. The transcription reactions were carried out under the conditions
recommended by the manufacturer (Promega), and the transcribed
RNAs were purified by denaturing gel electrophoresis.
The RNA transcripts for the target RNAs were subsequently
labeled with fluorescein according to the manufacturer’s protocol
(GE Healthcare). Briefly, after the removal of the 59-phosphates of
the transcribed RNAs with bacterial alkaline phosphatase (Takara
Shuzo), the RNAs were phosphorylated with T4 polynucleotide
kinase (Takara Shuzo) and ATPcS. Then a single fluorescein
moiety was appended onto the 59-phosphorothioate site. The
resulting fluorescein-labeled RNAs were gel-purified before assays.
The 59-half-tRNA
Glu (59-UCCCUGGUGGUCUAGUGGUU-
AGGAUUCGGCGCUCU-39), the 28S rRNA fragment (59-
UUGAAAGUCAGCCCUCGACACAAGGGUUUG-39), and
the four siRNAs [34] targeting the human Ago2 mRNA were
chemically synthesized by Nippon Bioservice. The siRNA
targeting the human tRNase Z
L mRNA was obtained from
Qiagen: sense, r(GACUCCGAGUCGAAUGAAA)d(TT); anti-
sense, r(UUUCAUUCGACUCGGAGUC)d(TG).
In vitro RNA cleavage assay
In vitro RNA cleavage assays [5,6] for the fluorescein-labeled
target RNAs (2 pmol) were carried out at 50uC in the presence of
the unlabeled small ncRNAs (20 pmol) using histidine-tagged
human tRNase Z
L (50 ng) in a mixture (6 ml) containing 10 mM
Tris-HCl (pH 7.5), 1.5 mM dithiothreitol, and 3.3 mM MgCl2.
After resolution of the reaction products on a 10–20% polyacryl-
amide-8 M urea gel, the gel was analyzed with a Typhoon 9210
(GE Healthcare).
Cell culture
The various human cells were cultured in Dulbecco’s modified
Eagle’s medium (DMEM; Sigma) supplemented with 10% fetal
bovine serum (FBS; MP Biomedicals) and 1% penicillin-strepto-
mycin (Invitrogen) at 37uCi n5 %C O 2 humidified incubator.
Transfection
The 293 cells were transfected with plasmids or with plasmids
and RNA using Lipofectamine 2000 (Invitrogen) according to the
manufacturer’s protocol. The cells were usually cultured for
further 18 h, and the cells transfected with the tRNase Z
L siRNA
or the Ago2 siRNAs were cultured for further 42 h.
Fluorescent microscopic analysis
Human cells were cultured on a 12-mm-diameter coverslip
coated with poly-D-lysine. For indirect fluorescent analysis, the
cells were fixed with 4% paraformaldehyde in phosphate-buffered
saline (PBS) for 10 min, permealized with HBS-PBS (5% horse
serum, 1% bovine serum albumin and 0.1% saponin in PBS) for
15 min, and incubated with primary tRNase Z
L antibodies for
3 h, and with an Alexa488-conjugated secondary antibody
(Invitrogen) for further 1 h. MitoTracker Red (Cambrex) was
used to stain the mitochondria according to the manufacturer’s
protocol, and DAPI (Sigma) was to stain DNA. The cells were
analyzed by the deconvolution method with the fluorescent
microscope system Axio Imager.M2 (Zeiss).
Western analysis
Whole cell extracts dissolved in a buffer (50 mM Tris-HCl
pH 6.8, 2% SDS, 10% glycerol, 100 mM dithiothreitol) or the
subcellular fractions described below were separated by SDS/7.5–
15% polyacrylamide gel electrophoresis, and transferred to a
nitrocellulose membrane. The membrane was probed with
antibodies raised to a human tRNase Z
L peptide (amino acid
812–826), recombinant human tRNase Z
S, or a human Ago2
peptide (amino acid 7–48; Upstate), or antibodies against the
standard proteins calpain, porin, c-jun, and vimentin using the
ECL Western Blotting Detection System (GE Healthcare).
Subcellular fractionation
Four subcellular fractions, cytosolic, membrane/organelle,
nuclear and cytoskeletal fractions, were prepared from 293 cells
by using a ProteoExtract Subcellular Proteome Extraction Kit
(Merckbiosciences).
Luciferase assay
The modified luciferase expression plasmids pGL3-T(tRNA) and
pGL3-T(rRNA), which produce mlucT(tRNA) and mlucT(rRNA),
respectively,wereconstructedbyinsertingannealedsyntheticdouble-
stranded DNAs containing the sequences T(tRNA) (59-CGC-
CGCTGGGTTGGATTCCCAGCCAGGGA-39)a n dT ( r R N A )
(59-GACTTTCTT-39), respectively, between Xba Ia n dFse Is i t e s
of pGL3-Control vector (Promega).
The 293 cells were plated at densities of 2610
5 cells/ml on 24-
well dishes in 500 ml/well DMEM supplemented with 10% FBS.
After incubation at 37uC for 24 h, the cells were co-transfected
with 0.2 mg/ml of one of the pGL3 series plasmids and 0.2 mg/ml
of the b-galactosidase expression plasmid pTK-b (Clontech)
together with chemically synthesized 59-half-tRNA
Glu (100 nM),
the 28S rRNA fragment (100 nM), the human tRNase Z
L or
tRNase Z
S expression plasmid (0.5 mg/ml), the human tRNase Z
L
siRNA (100 nM), or the four human Ago2 siRNAs (25 nM each).
After further 18- or 42-h incubation, the cells were harvested, and
the luciferase and b-galactosidase activities were measured using a
PicaGene Kit (Toyo Ink) and a b-Gal Reporter Gene Assay Kit
(Roche), respectively, with a Veritas Microplate Luminometer
(Promega). The luciferase activity was normalized against the b-
galactosidase activity.
Real-time PCR for luciferase mRNA quantitation
The total RNAs from the 293 cells that were co-transfected with
one of the pGL3 series plasmids (0.2 mg/ml) and the human tRNase
Z
L expression plasmid (0.5 mg/ml) or the human tRNase Z
L siRNA
(100 nM)wereextractedwithISOGEN.Thelevelsofluciferase and
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) mRNAs
were quantitated by real-time PCR using a LightCycler 480 SYBR
Green I Kit (Roche). The luciferase mRNA level was normalized
against the GAPDH mRNA level. The primerpair forthe luciferase
mRNA was 59-TCTGGATCTACTGGTCTGCCTAA-39 and 59-
GCGCACTTTGAATCTTGTAATCCTG-39, and that for the
GAPDH mRNA was 59-CTCTTGTGCTCTTGCTGGG-39 and
59-ACCCATCCTCCACCTTTG-39.
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The total RNAs from the 293 cells that were transfected with
one of the pGL3 series plasmids (0.2 mg/ml) were extracted with
ISOGEN. The luciferase mRNA fragments generated by
cleavages in its 39 UTR were amplified by reverse-transcription
PCR. After adding the linker 59-r(UUU)d(AACCGCGAATTC-
CAG)-39 to the 39 ends, the fragments with the linker were
subjected to reverse transcription, and the resulting cDNAs were
amplified first using the primer pair 59-ACGTCGCCAGTCAAG-
TAACA-39 and 59-GACTAGCTGGAATTCGCGGTTAAA-39
and then using the primer pair 59-TCCCCGCGGGGAAGGC-
CAAGAAGGGCGGAAAGA-39 and 59-GACTAGCTGGA-
ATTCGCGGTTAAA-39. The PCR products of ,100 bp were
recovered from an agarose gel, cloned into the TA cloning vector
pGEM-T (Promega), and sequenced.
Likewise, 39 RACE for the human PPM1F mRNA fragments
was carried out. The cDNAs were amplified first using the primer
pair 59-CCCACAGAAGAGCAGCCCAA-39 and 59-GAC-
TAGCTGGAATTCGCGGTTAAA-39 and then using the prim-
er pair 59-TCCTGGACACGCTCCTGCAA-39 and 59-GAC-
TAGCTGGAATTCGCGGTTAAA-39.
Co-immunoprecipitation
The 293 cell total extracts prepared basically as described
previously [1] were incubated for 1 h with the human tRNase Z
L
antibodies attached to Protein A sepharose (Sigma). As a negative
control, bovine serum albumin was used instead of the antibodies.
After washing the sepharose with a buffer (150 mM NaCl, 50 mM
Tris-HCl, pH 7.4, 0.05% Nonidet P-40) 6 times, RNA compo-
nents were extracted with phenol/chloroform, and precipitated
with ethanol. The precipitated RNA samples were amplified by
reverse-transcription PCR basically according to Pfeffer et al’s
method [35], and cDNAs of ,30 bp were cloned and sequenced.
Northern analysis
RNAs from nuclei and cytoplasm of the 293 cells that were
separated by using a Paris Kit (Ambion), and total RNA were
extracted with ISOGEN. The RNA samples (4 mg of nuclear
RNA, 24 mg of cytoplasmic RNA, and 30 mg of total RNA) were
separated by 10% polyacrylamide/8 M urea gel electrophoresis,
and electrically transferred to a Hybond N
+ membrane (GE
Healthcare). The DynaMarker small RNA II (BioDynamics) was
used as RNA size standards after 59-fluorescein-labeling. The
membrane was ultraviolet-crosslinked, probed with a 59-
32P-
labeled deoxyoligonucleotide in a QuickHyb buffer (Stratagene) at
45uC, and analyzed with a Typhoon 9210.
DNA microarray analysis
Total RNA was extracted with ISOGEN from the 293 cells
transfected with or without the human tRNase Z
L expression
plasmid (0.5 mg/ml). The samples were hybridized to a GeneChip
Human Genome U133 Plus 2.0 Array (Affymetrix), and analyzed
using Microarray Suite version 5.0 according to the manufactur-
er’s protocol.
PCR analyses for endogenous mRNAs
Total RNA was extracted with ISOGEN from the 293 cells
transfected with the 28S rRNA fragment (0.1 mM) or 59-half-
tRNA
Glu (0.1 mM) and/or the tRNase Z
L expression plasmid
(0.2 mg/ml). For non-real-time PCR analysis, cDNA synthesis for
1 mg of the total RNAwas carried out using a PrimeScript RT-PCR
Kit (Takara Shuzo), and PCR for the cDNA was using Ex Taq
DNA polymerase (Takara Shuzo) and each mRNA (or rRNA)
specific primer pair (Table S3). PCR products were separated on a
1.5% agarose gel and stained with ethidium bromide.
For real-time PCR analysis, mRNA and 28S rRNA levels were
quantitated using a Transcriptor First Strand cDNA Synthesis Kit
(Roche), a LightCycler Taqman Master (Roche), and each mRNA
(or rRNA) specific primer pair and probe (Table S3). The first
strand cDNA synthesis for mRNA was performed using an
oligo(dT)18 primer. The mRNA level was normalized against the
28S rRNA level.
Statistical analysis
Differences between control and experimental groups were
evaluated by the Student’s t-test.
Accession numbers
Small ncRNA sequences were deposited in the DNA Data Bank
of Japan (www.ddbj.nig.ac.jp), accessions AB330769–AB330794,
and microarray data were in Gene Expression Omnibus (http://
www.ncbi.nlm.nih.gov/geo), accession GSE12524.
Supporting Information
Figure S1 Northern blotting for small ncRNAs co-immunopre-
cipitated with human tRNase Z
L. The probe sequence of each
ncRNA is indicated in Table S1. Vertical bars denote the small
ncRNAs. The nuclear and cytoplasmic RNAs were probed for U3
snRNA to evaluate the integrity of the nuclear/cytoplasmic
fractionation. U3 snRNA probe sequence, 59-
GACCGCGTTCTCTCCTTCTCACTCCCCAAT-39; T, total
RNA; N, nuclear RNA; C, cytoplasmic RNA. The presence of a
smaller amount of 59-half-tRNA
Glu in the total RNA of 293 cells
than in the fraction RNAs is because the total RNA was prepared
from the cells with a lower density (Figure S8A).
Found at: doi:10.1371/journal.pone.0005908.s001 (0.08 MB
PDF)
Figure S2 Differential interference contrast (DIC) and fluores-
cent (Alexa488) microscopic images of human 293 kidney cells,
A549 epithelial lung cells, HepG2 hepatoma cells, and IMR90
lung fibroblasts. The pictures in the right panels, which are
negative controls for the ones in Figure 3, were taken under the
conditions that the cells were incubated with an Alexa488-
conjugated secondary antibody without being incubated with
primary tRNase Z
L antibodies. Bar, 20 mm.
Found at: doi:10.1371/journal.pone.0005908.s002 (1.48 MB
PDF)
Figure S3 DNA microarray analysis. (A) mRNAs downregulat-
ed by tRNase Z
L overexpression. (B) and (C) The KEGG pathway
analysis. The p53 signaling pathway (B) and apoptosis (C) are
shown. Red and blue squares denote genes upregulated and
downregulated, respectively, by tRNase Z
L overexpression.
Found at: doi:10.1371/journal.pone.0005908.s003 (0.38 MB
PDF)
Figure S4 Reverse-transcription PCR analyses for selected
mRNAs. Total RNA samples were prepared from the 293 cells
that were transfected with the 28S rRNA fragment (+rRNA), 59-
half-tRNA
Glu (+tRNA), or the tRNase Z
L expression plasmid
(+Z
L). The numbers of potential target sites in the mRNAs for the
28S rRNA fragment and 59-half-tRNA
Glu are shown.
Found at: doi:10.1371/journal.pone.0005908.s004 (1.88 MB
PDF)
Figure S5 Possible secondary structures of 59-half-tRNA
Glu/
PPM1F mRNA complexes. Arrows denote expected cleavage sites.
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of the PPM1F mRNA sequence (GenBank accession
NM_014634).
Found at: doi:10.1371/journal.pone.0005908.s005 (0.22 MB
PDF)
Figure S6 Distribution of 39 ends of 59 cleavage products of the
human PPM1F mRNA. The 39 ends were determined by 39
RACE for total RNA from the 293 cells. Red line, expected
cleavage site. Numbers on the PPM1F mRNA are from the
numbering system of the PPM1F mRNA sequence (GenBank
accession NM_014634).
Found at: doi:10.1371/journal.pone.0005908.s006 (0.21 MB
PDF)
Figure S7 Conservation of potential ncRNA-guided tRNase Z
L
target sequences among human, mouse, and rat. (A) Comparison
of potential 59-half-tRNA
Glu-guided tRNase Z
L target sequences
in the human PPM1F mRNA with the corresponding sequences in
the mouse and rat PPM1F mRNAs. Mouse and rat PPM1F
mRNA sequences corresponding to the third target sequence in
the 39 UTR of the human PPM1F mRNA are not discernible. (B)
Comparison of potential 28S-rRNA-fragment-guided tRNase Z
L
target sequences in the human DYNC1H1 mRNA with the
corresponding sequences in the mouse and rat DYNC1H1
mRNAs. Potential ncRNA-binding nucleotides and potential
nucleotides that form T-stem-like structures are shown in red
and in blue, respectively. Nucleotides in the mouse and rat
sequences that are different from those in the human sequences
are underscored. Numbers on the human PPM1F and DYNC1H1
mRNA sequences are from the numbering systems of the PPM1F
mRNA sequence (GenBank accession NM_014634) and the
DYNC1H1 mRNA sequence (GenBank accession NM_001376),
respectively.
Found at: doi:10.1371/journal.pone.0005908.s007 (0.21 MB
PDF)
Figure S8 Northern analyses for small ncRNAs that work as
sgRNAs. (A) Time course analysis for the levels of the 59-half-
tRNA
Glu (vertical bar) in 293 and HeLa cells, which were plated at
the densities of 2610
5 and 1610
5 cells/ml, respectively. (B) Time
course of the level of the RNase 65 RNA component 39-truncated
tRNA
Arg in human BJAB cells cultured in RPMI medium
containing 10% FBS after adding 5-fluorouracil (400 mM). The
tRNA
Arg probe sequence, 59-GAATCTTCTGATCCGTAG-39.
Found at: doi:10.1371/journal.pone.0005908.s008 (0.49 MB
PDF)
Table S1 Small RNAs co-immunoprecipitated with human
tRNase Z
L.
Found at: doi:10.1371/journal.pone.0005908.s009 (0.02 MB
PDF)
Table S2 Potential mRNA targets of tRNase Z
L guided by 59-
half-tRNA
Glu.
Found at: doi:10.1371/journal.pone.0005908.s010 (0.17 MB
PDF)
Table S3 PCR primers and probes for endogenous mRNA
analyses.
Found at: doi:10.1371/journal.pone.0005908.s011 (0.05 MB
PDF)
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